Diabetes Metab J.  2012 Oct;36(5):345-349. 10.4093/dmj.2012.36.5.345.

C-Peptide and Vascular Complications in Type 2 Diabetic Subjects

• Son SM

• KMID: 2174392
• DOI: http://doi.org/10.4093/dmj.2012.36.5.345

Abstract

No abstract available.

MeSH Terms

C-Peptide
C-Peptide

Reference

1. Steiner DF, Cunningham D, Spigelman L, Aten B. Insulin biosynthesis: evidence for a precursor. Science. 1967. 157:697–700.

2. Wahren J, Shafqat J, Johansson J, Chibalin A, Ekberg K, Jornvall H. Molecular and cellular effects of C-peptide: new perspectives on an old peptide. Exp Diabesity Res. 2004. 5:15–23.

3. Zhong Z, Kotova O, Davidescu A, Ehren I, Ekberg K, Jornvall H, Wahren J, Chibalin AV. C-peptide stimulates Na+, K+-ATPase via activation of ERK1/2 MAP kinases in human renal tubular cells. Cell Mol Life Sci. 2004. 61:2782–2790.

4. Munte CE, Vilela L, Kalbitzer HR, Garratt RC. Solution structure of human proinsulin C-peptide. FEBS J. 2005. 272:4284–4293.

5. Prando R, Odetti P, Melga P, Giusti R, Ciuchi E, Cheli V. Progressive deterioration of beta-cell function in nonobese type 2 diabetic subjects. Postprandial plasma C-peptide level is an indication of insulin dependency. Diabetes Metab. 1996. 22:185–191.

6. Haupt E, Haupt A, Herrmann R, Benecke-Timp A, Vogel H, Walter C. The KID Study V: the natural history of type 2 diabetes in younger patients still practising a profession. Heterogeneity of basal and reactive C-peptide levels in relation to BMI, duration of disease, age and HbA1. Exp Clin Endocrinol Diabetes. 1999. 107:236–243.

7. Horwitz DL, Rubenstein AH, Katz AI. Quantitation of human pancreatic beta-cell function by immunoassay of C-peptide in urine. Diabetes. 1977. 26:30–35.

8. Aoki Y. Variation of endogenous insulin secretion in association with treatment status: assessment by serum C-peptide and modified urinary C-peptide. Diabetes Res Clin Pract. 1991. 14:165–173.

9. Hills CE, Brunskill NJ, Squires PE. C-peptide as a therapeutic tool in diabetic nephropathy. Am J Nephrol. 2010. 31:389–397.

10. McDonald TJ, Knight BA, Shields BM, Bowman P, Salzmann MB, Hattersley AT. Stability and reproducibility of a single-sample urinary C-peptide/creatinine ratio and its correlation with 24-h urinary C-peptide. Clin Chem. 2009. 55:2035–2039.

11. Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care. 2003. 26:832–836.

12. Panero F, Novelli G, Zucco C, Fornengo P, Perotto M, Segre O, Grassi G, Cavallo-Perin P, Bruno G. Fasting plasma C-peptide and micro- and macrovascular complications in a large clinic-based cohort of type 1 diabetic patients. Diabetes Care. 2009. 32:301–305.

13. Ekberg K, Brismar T, Johansson BL, Jonsson B, Lindstrom P, Wahren J. Amelioration of sensory nerve dysfunction by C-Peptide in patients with type 1 diabetes. Diabetes. 2003. 52:536–541.

14. Ekberg K, Brismar T, Johansson BL, Lindstrom P, Juntti-Berggren L, Norrby A, Berne C, Arnqvist HJ, Bolinder J, Wahren J. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy. Diabetes Care. 2007. 30:71–76.

15. Samnegard B, Jacobson SH, Jaremko G, Johansson BL, Ekberg K, Isaksson B, Eriksson L, Wahren J, Sjoquist M. C-peptide prevents glomerular hypertrophy and mesangial matrix expansion in diabetic rats. Nephrol Dial Transplant. 2005. 20:532–538.

16. Sjoquist M, Huang W, Johansson BL. Effects of C-peptide on renal function at the early stage of experimental diabetes. Kidney Int. 1998. 54:758–764.

17. Wallerath T, Kunt T, Forst T, Closs EI, Lehmann R, Flohr T, Gabriel M, Schafer D, Gopfert A, Pfutzner A, Beyer J, Forstermann U. Stimulation of endothelial nitric oxide synthase by proinsulin C-peptide. Nitric Oxide. 2003. 9:95–102.

18. Kamikawa A, Ishii T, Shimada K, Makondo K, Inanami O, Sakane N, Yoshida T, Saito M, Kimura K. Proinsulin C-peptide abrogates type-1 diabetes-induced increase of renal endothelial nitric oxide synthase in rats. Diabetes Metab Res Rev. 2008. 24:331–338.

19. Sima AA, Zhang W, Grunberger G. Type 1 diabetic neuropathy and C-peptide. Exp Diabesity Res. 2004. 5:65–77.

20. Forst T, Kunt T, Wilhelm B, Weber MM, Pfutzner A. Role of C-peptide in the regulation of microvascular blood flow. Exp Diabetes Res. 2008. 2008:176245.

21. Joshua IG, Zhang Q, Falcone JC, Bratcher AP, Rodriguez WE, Tyagi SC. Mechanisms of endothelial dysfunction with development of type 1 diabetes mellitus: role of insulin and C-peptide. J Cell Biochem. 2005. 96:1149–1156.

22. Kitamura T, Kimura K, Makondo K, Furuya DT, Suzuki M, Yoshida T, Saito M. Proinsulin C-peptide increases nitric oxide production by enhancing mitogen-activated protein-kinase-dependent transcription of endothelial nitric oxide synthase in aortic endothelial cells of Wistar rats. Diabetologia. 2003. 46:1698–1705.

23. Bo S, Cavallo-Perin P, Gentile L, Repetti E, Pagano G. Relationship of residual beta-cell function, metabolic control and chronic complications in type 2 diabetes mellitus. Acta Diabetol. 2000. 37:125–129.

24. Sari R, Balci MK. Relationship between C peptide and chronic complications in type-2 diabetes mellitus. J Natl Med Assoc. 2005. 97:1113–1118.

25. Kim BY, Jung CH, Mok JO, Kang SK, Kim CH. Association between serum C-peptide levels and chronic microvascular complications in Korean type 2 diabetic patients. Acta Diabetol. 2012. 49:9–15.

26. Yoon HJ, Cho YZ, Kim JY, Kim BJ, Park KY, Ko GP, Lee DH, Lim DM. Correlations between glucagon stimulated C-peptide levels and microvascular complications in type 2 diabetes patients. Diabetes Metab J. 2012. 36:379–387.

27. Bo S, Gentile L, Castiglione A, Prandi V, Canil S, Ghigo E, Ciccone G. C-peptide and the risk for incident complications and mortality in type 2 diabetic patients: a retrospective cohort study after a 14-year follow-up. Eur J Endocrinol. 2012. 167:173–180.

28. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002. 287:2570–2581.

29. Marx N, Walcher D, Raichle C, Aleksic M, Bach H, Grub M, Hombach V, Libby P, Zieske A, Homma S, Strong J. C-peptide colocalizes with macrophages in early arteriosclerotic lesions of diabetic subjects and induces monocyte chemotaxis in vitro. Arterioscler Thromb Vasc Biol. 2004. 24:540–545.

30. Al-Rasheed NM, Chana RS, Baines RJ, Willars GB, Brunskill NJ. Ligand-independent activation of peroxisome proliferator-activated receptor-gamma by insulin and C-peptide in kidney proximal tubular cells: dependent on phosphatidylinositol 3-kinase activity. J Biol Chem. 2004. 279:49747–49754.

31. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999. 340:115–126.

32. Bittl JA. Advances in coronary angioplasty. N Engl J Med. 1996. 335:1290–1302.

33. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation. 2004. 109:1942–1947.

34. Walcher D, Marx N. C-Peptide in the vessel wall. Rev Diabet Stud. 2009. 6:180–186.

35. Walcher D, Babiak C, Poletek P, Rosenkranz S, Bach H, Betz S, Durst R, Grub M, Hombach V, Strong J, Marx N. C-peptide induces vascular smooth muscle cell proliferation: involvement of SRC-kinase, phosphatidylinositol 3-kinase, and extracellular signal-regulated kinase 1/2. Circ Res. 2006. 99:1181–1187.

36. Harbour JW, Dean DC. Rb function in cell-cycle regulation and apoptosis. Nat Cell Biol. 2000. 2:E65–E67.

37. Mughal RS, Scragg JL, Lister P, Warburton P, Riches K, O'Regan DJ, Ball SG, Turner NA, Porter KE. Cellular mechanisms by which proinsulin C-peptide prevents insulin-induced neointima formation in human saphenous vein. Diabetologia. 2010. 53:1761–1771.

38. Mavrakanas T, Frachebois C, Soualah A, Aloui F, Julier I, Bastide D. C-peptide and chronic complications in patients with type-2 diabetes and the metabolic syndrome. Presse Med. 2009. 38:1399–1403.